PDCD1 and kidney neoplasm: Based on our experience, as shown in this study, immune-targeting of the PD1/PDL1 pathway could be a very promising strategy, worthy of further exploration, particularly in extended hospital settings where international networks of experts are connected in order to gather data and experience and to approach rare kidney tumors on a larger scale.